Bausch Health Companies Inc. (TSE:BHC - Get Free Report) shares were up 0.3% during trading on Monday . The company traded as high as C$7.56 and last traded at C$7.50. Approximately 128,862 shares traded hands during mid-day trading, a decline of 74% from the average daily volume of 503,122 shares. The stock had previously closed at C$7.48.
Analyst Ratings Changes
A number of analysts have recently commented on BHC shares. Raymond James Financial upgraded Bausch Health Companies to a "hold" rating in a research note on Monday, December 15th. Barclays upgraded Bausch Health Companies to a "hold" rating in a research note on Monday, December 8th. Two analysts have rated the stock with a Hold rating, According to MarketBeat, the stock presently has an average rating of "Hold".
Read Our Latest Stock Analysis on BHC
Bausch Health Companies Stock Up 0.3%
The stock has a market cap of C$2.78 billion, a PE ratio of 17.86, a P/E/G ratio of 0.21 and a beta of 0.59. The business has a 50 day moving average price of C$7.65 and a 200 day moving average price of C$8.72. The company has a quick ratio of 0.58, a current ratio of 1.47 and a debt-to-equity ratio of -3,835.02.
Bausch Health Companies (TSE:BHC - Get Free Report) last issued its quarterly earnings results on Wednesday, February 18th. The company reported C($0.41) earnings per share (EPS) for the quarter. The business had revenue of C$6.62 billion for the quarter. Bausch Health Companies had a negative return on equity of 20.27% and a net margin of 1.82%. Equities research analysts expect that Bausch Health Companies Inc. will post 5.5472637 EPS for the current fiscal year.
Bausch Health Companies Company Profile
(
Get Free Report)
Bausch Health Companies Inc is a global company that develops manufactures and markets a range of pharmaceutical medical device and over-the-counter products primarily in the therapeutic areas of eye health gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. Our approximately 22000 employees are united around our mission of improving peoples lives with our health care products and we manufacture and market health care products directly or indirectly in approximately 100 countries.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
